NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it will collaborate with Proteome Sciences to develop quantitative proteomic workflows for biomarker discovery and validation.
The alliance will combine Proteome Sciences' isobaric mass tagging reagents with Thermo Fisher's mass spectrometry systems. Thermo Fisher said that Proteome Sciences has installed LTQ Orbitrap Velos and TSQ Vantage mass spec systems at its research labs in Frankfurt, Germany, to extend its biomarker discovery and validation workflows.
"When using the TSQ Vantage high-sensitivity triple quadrupole mass spectrometer in combination with our proprietary TMT tandem mass tag technology for assay development, we can offer the most integrated biomarker discovery, qualification, and assay validation workflows in the industry," Proteome Sciences COO Ian Pike said in a statement. "We have already successfully used TMT technology to develop mass spec assays for blood biomarkers in Alzheimer's disease and are extending our coverage for other proprietary biomarkers in cancer and brain damage."
Thermo Fisher noted that over the past three years Proteome Sciences has been working with researchers at its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center to adapt workflows for isotope dilution mass spectrometry assays based on the technique of selected reaction monitoring.
Proteome Sciences intends to expand its relationship with BRIMS to develop biomarker assays in Alzheimer's disease and cancer for clinical research applications.